Press releases
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Wednesday, Ligand Pharmaceuticals Inc (LGNXZ:PKC) closed at 0.009, -47.06% below its 52-week high of 0.017, set on Jun 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0015 |
---|---|
High | 0.009 |
Low | 0.0015 |
Bid | -- |
Offer | -- |
Previous close | 0.009 |
Average volume | 1.95k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 22 2024 14:30 BST.
More ▼